ecteinascidin 743 has been researched along with glutamine in 2 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (glutamine) | Trials (glutamine) | Recent Studies (post-2010) (glutamine) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 19,062 | 787 | 5,408 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Crescenzi, E; D'Incalci, M; Leonardi, A; Mellone, S; Pacifico, F; Stornaiuolo, M | 1 |
2 other study(ies) available for ecteinascidin 743 and glutamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.
Topics: Amino Acid Transport System ASC; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Glutamine; Humans; Minor Histocompatibility Antigens; Neoplasms; Neoplastic Stem Cells; Trabectedin | 2022 |